Table 3

Clinical characteristics in those with interstitial lung disease, cardiac involvement, malignancy and dysphagia within the EuroMyositis Registry

Interstitial lung disease
720/2442 (30%)		Cardiac involvement
156/1715 (9%)		Malignancy
374/2788 (13%)		Dysphagia
767/1945 (39%)		Total
n (%)
Present Absent p Value Present Absent p Value Present Absent p Value Present Absent p Value
Mean age at IIM disease onset in years (SD)49 (15)49 (17)0.90350 (14)49 (17)0.60257 (14)48 (16) <0.001 51 (15)48 (17) <0.001 49 years (SD 16)
Gender (% male)31330.38737330.43633320.74036330.173944/3002 (32)
Current or previous smoking (%)4135 0.013 5534 <0.001 5137 <0.001 4234 0.001 611/1646 (37)
Environmental toxin exposure (%)2214 0.004 2714 0.006 20180.6342015 0.060 157/930 (17)
Median number of recorded medications used to treat myositis (IQR)2 (2–4)2 (1–3) <0.001 3 (2–4)2 (1–3) 0.016 2 (1–3)2 (2–3)0.1232 (2–3)2 (1–3) 0.042 two medications (IQR 1–3)
Disease severity assessments at last visit— median (IQR) Median (IQR), n
MMT-8 score (0–80)73
(66-78)		74
(63-79)		0.78067
(61-77)		73
(62-78)		0.20070
(61-78)		74
(63-79)		0.37771
(59-78)		73
(64-78)		 0.044 73
(63-79), 442
Physician-completed global disease activity VAS (0–100)11
(3-25)		9
(0–24)		0.11911
(5-26)		11 (2–28)0.4687
(1-25)		10
(2-26)		0.46910
(2-28)		10
(2-25)		0.13510
(1-26), 772
Patient-completed global disease activity VAS (0–100)42
(14-57)		38
(10-60)		0.29950
(31-66)		41
(12-59)		 0.007 47
(24-64)		38
(10-55)		 0.009 46
(17-65)		37
(10-53)		 0.007 40
(11-57), 587
HAQ-DI (0–3)0.75
(0.13–1.38)		0.70
(0.13–1.37)		0.2721.00
(0.38–1.63)		0.67
(0.13–1.38)		 0.012 1.13
(0.63–1.63)		0.63
(0.13–1.38)		 <0.001 1.00
(0.25–1.63)		0.63
(0.13–1.13)		 <0.001 0.75
(0.13–1.50), 692
Creatine kinase (as ratio of ULN)0.45
(0.33–1.18)		0.67
(0.41–2.00)		0.5420.87
(0.66–2.19)		0.66
(0.40–2.05)		0.7120.40
(0.23–0.58)		0.66
(0.39–1.85)		0.320.63
(0.34–1.32)		0.71
(0.39–2.21)		0.2590.63
(0.37–1.78), 208
Extramuscular disease activity VAS (0–100)10
(2-22)		3
(0–15)		 0.001 12
(3-25)		7 (0–19) 0.017 5
(0–19)		6
(0–18)		0.5487
(0–21)		5
(0–16)		 0.003 5
(0–18), 702
Myositis Damage Index global VAS (0–100)25
(13-40)		14
(4-37)		 0.005 31
(12-48)		20 (5–38) 0.047 37
(22-53)		17
(5-35)		 <0.001 25
(10-43)		17
(3-32)		 0.001 20
(6-38), 421

  • Environmental toxin exposure includes exposure to asbestos, silica, fibreglass, solvents or coal dust. p Values are derived from a logistic regression model that includes adjustment for time since disease onset where data from the last patient visit are analysed. Values in bold signify p<0.05.

  • HAQ-DI, Health Assessment Questionnaire-Disability Index; VAS, visual analogue scale; MMT-8, manual muscle test-8 score; ULN, upper limit of normal.